.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Farmers Insurance
Merck
Citi
US Army
Healthtrust
QuintilesIMS
Baxter
Moodys
Colorcon

Generated: December 12, 2017

DrugPatentWatch Database Preview

VENLAFAXINE HYDROCHLORIDE Drug Profile

« Back to Dashboard

When do Venlafaxine Hydrochloride patents expire, and what generic alternatives are available?

Venlafaxine Hydrochloride is a drug marketed by Anchen Pharms, Aurobindo Pharma Ltd, Dr Reddys Labs Ltd, Macleods Pharms Ltd, Mylan, Orchid Hlthcare, Teva, Torrent Pharms Llc, Valeant Pharms North, Wockhardt, Zydus Pharms Usa Inc, Nostrum Labs Inc, Osmotica Pharm, Sun Pharma Global, Alembic Pharms Ltd, Amneal Pharms, Aurobindo Pharma, Heritage Pharms Inc, Pliva Hrvatska Doo, Prinston Inc, Sandoz, Sun Pharm Inds Inc, Yaopharma Co Ltd, and Zydus Pharms Usa. and is included in twenty-seven NDAs. There are two patents protecting this drug.

This drug has ninety-two patent family members in forty-four countries.

The generic ingredient in VENLAFAXINE HYDROCHLORIDE is venlafaxine hydrochloride. There are seventy-one drug master file entries for this compound. Seventy-five suppliers are listed for this compound. There are two tentative approvals for this compound. Additional details are available on the venlafaxine hydrochloride profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Dr Reddys Labs LtdVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET;ORAL078301-003Jun 13, 2008ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Sun Pharm Inds IncVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET;ORAL078627-002Jun 13, 2008ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Zydus Pharms Usa IncVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL090174-002Apr 14, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Pliva Hrvatska DooVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET;ORAL078517-002Jun 13, 2008DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Yaopharma Co LtdVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET;ORAL202036-005May 28, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Yaopharma Co LtdVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET;ORAL202036-002May 28, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Amneal PharmsVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET;ORAL079098-001May 11, 2010ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Zydus Pharms UsaVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET;ORAL077653-003Jun 13, 2008ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Sun Pharm Inds IncVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET;ORAL078627-003Jun 13, 2008ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Osmotica PharmVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022104-004May 20, 2008ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VENLAFAXINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Osmotica PharmVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022104-003May 20, 2008► Subscribe► Subscribe
Osmotica PharmVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022104-001May 20, 2008► Subscribe► Subscribe
Osmotica PharmVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022104-004May 20, 2008► Subscribe► Subscribe
Osmotica PharmVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022104-003May 20, 2008► Subscribe► Subscribe
Osmotica PharmVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022104-002May 20, 2008► Subscribe► Subscribe
Osmotica PharmVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022104-002May 20, 2008► Subscribe► Subscribe
Osmotica PharmVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022104-004May 20, 2008► Subscribe► Subscribe
Osmotica PharmVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022104-001May 20, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: VENLAFAXINE HYDROCHLORIDE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,274,171 Extended release formulation of venlafaxine hydrochloride► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VENLAFAXINE HYDROCHLORIDE

Country Document Number Estimated Expiration
Hungary224617► Subscribe
Turkey200001232► Subscribe
Australia1640097► Subscribe
South Africa9810081► Subscribe
Czech Republic20001659► Subscribe
Hong Kong1056686► Subscribe
New Zealand504460► Subscribe
Egypt24198► Subscribe
Argentina014012► Subscribe
El Salvador1998000131► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Baxter
Queensland Health
US Department of Justice
Johnson and Johnson
Daiichi Sankyo
Fish and Richardson
Novartis
Dow
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot